Investor Presentation Q1-Q3 2020

65 Investor presentation First nine months of 2020 Phase 3 programme on-going investigating concizumab for haemophilia A and B irrespective of inhibitor status Phase 3 trials with data expected first half of 2021 Novo NordiskⓇ Arm 1: No prophylaxis Arm 2: Concizumab prophylaxis Arm 3: Concizumab prophylaxis Exp7 and Exp8: On-demand treatment Exp7 and Exp8: Phase 2 patients on concizumab prophylaxis Exp7 (with inhibitors): Prophylaxis with bypassing or on-demand Arm 4: Concizumab prophylaxis Extension with concizumab prophylaxis . . Characteristics and next steps High affinity, humanised monoclonal IgG4 antibody First-in-class anti-TFPI boosting the initiation phase to restore haemostasis • Delivered once-daily in a convenient Flextouch® pen • Safe and well-tolerated in phase 2 and efficacy comparable to factor replacement Exp8 (without inhibitors): Prophylaxis with factor replacement or on-demand Main part: 24 weeks treatment < Extension: Up to 136 weeks treatment

View entire presentation